Abstract
Introduction
Obesity and overweight are linked with a cluster of metabolic and vascular disorders that have been termed the metabolic syndrome, characterized by impaired insulin sensitivity, hyperglycaemia, dyslipidaemia, obesity and hypertension. It has been estimated [1] that the syndrome affects a substantial percentage (10-20%) 
of the middle-aged and elderly populations of most
European countries, and confers increased risk for type 2 diabetes (2-8.8-fold) and cardiovascular disease (1.5-6-fold) , that ultimately will lead to economically unsustainable costs of health care in the next 10-20 years [2, 3] . The metabolic syndrome might be also an important factor in the cause of chronic kidney disease which is a major risk factor for end-stage renal disease and premature death [4] . Preventive strategies are required to slow the progression of the metabolic syndrome complications, and the research in this field has been facilitated by the availability of a hyperlipidaemic, non-diabetic animal model of nephropathy, the Zucker fa/fa rat. This rat model, showing many features of human syndrome X [5, 6] is not only hyperlipidaemic and obese (resulting from a homozygous defect in the leptin heparin receptor) but also hypertensive, insulin resistant and highly susceptible to the development of chronic renal disease in the absence of hyperglycaemia [7, 8] .
Using this animal model, Alderson et al. [9] [10] . Lipid peroxides and 8-epi-PGF2␣, a specific marker of oxidative stress, were doubled in the plasma of Zucker rats as compared to lean controls [11] . More [12, 13] [14] . In particular, the increased urinary amount of CAR-HNE, recognized in previous in vitro studies as a new potential biomarker of carbonyl stress [15] [10, 16, 17] [10, 16, 17] [15, [18] [19] [20] [21] . Up to now several studies reported a beneficial effect of CAR. Hipkiss reviewed the possible beneficial effects of CAR and related structures on protein carbonyl stress, AGE formation, secondary diabetic complications and age-related neuropathology [22] . Over the last 5 years, two independent studies have found an association between a trinucleotide repeat in exon 2 of the carnosine dipeptidase (CNDP)1 gene, which encodes carnosinase and diabetic nephropathy [23, 24] [25] , diabetes-related diseases [26, 27] , brain, heart and renal ischemia damage [28] [29] [30] [31] and bleomycin-induced lung injury [32] 
demonstrated that a long-term administration of pyridoxamine, a potent inhibitor of advanced lipoxidation end products (ALEs), restrained ALEs and advanced glycation end product (AGE) formation and hyperlipidaemia, preventing renal and vascular injury. This protective effect is explained by taking into account that the chemical modification of proteins by lipoxidation breakdown products is considered a primary cause of vascular and renal disease in fa/fa rats, even in the absence of hyperglycaemia. An excessive or sustained increase in reactive oxygen species (ROS) and lipoxidation products (reactive carbonyl species, RCS) has indeed been implicated in the pathogenesis of several diseases, as well as in the co-morbidity of atherosclerosis and diabetes mellitus associated with obesity

recently, the involvement of lipid peroxidation in the renal injury of Zucker rats has been immunohistochemically demonstrated by the heavy deposition of 4-hydroxy-trans-2-nonenal (HNE) adducts with proteins in glomeruli and renal arteries
, and by the increased urinary excretion of carbonylation biomarkers, such as 1,4-dihydroxynonane mercapturic acid (DHN-MA), carnosine-HNE (CAR-HNE), His-1,4-dihydroxynonane (His-DHN), all arising by Michael adduction of HNE to cysteine and histidine-containing peptides
. In this context, the most promising therapeutic approach to prevent/inhibit carbonyl stress-related diseases is based on those compounds able to deactivate the intermediate products of lipid peroxidation (as shown for pyridoxamine) or to scavenge/neutralize RCS, leading to non-reactive and non-cytotoxic reaction products. The clinical evidence that aldehyde-sequestering agents act as protective drugs is still limited to pyridoxamine (being now on the FDA 'fast track' to phase III clinical trials for prevention of diabetic nephropathy), and for this reason the development of novel aldehyde sequestering agents represents an emerging field of interest in medicinal chemistry. Although there is ample experimental evidence demonstrating the protective effects of several RCS scavengers in in vitro models and in some animal models, greater effort is required to confirm their carbonyl trapping capacity in vivo
. In previous studies we have demonstrated that L-CAR, besides its ability to act as an antioxidant, metal chelator, free radical scavenger and/or inhibitor of protein glycosylation, is an efficient and selective quencher of reactive and cytotoxic carbonyl species generated by lipooxidation, such as HNE and acrolein (ACR)
Computational studies
The homology model for human serum carnosinase was obtained based on ␤-alanine synthetase, as previously described [34] . L-and D-carnosine were built using the VEGA software ( Alderson et al. in the same experimental model [9] . 
untreated obese control (ZK), L-CARtreated (ZK ϩ L) and D-CAR-treated (ZK ϩ D) animals. D-CAR and L-CAR were administered to fa/fa rats in the drinking water. Water consumption was monitored, and the concentration of both L-and D-CAR in the drinking water was adjusted weekly with the intended 24 hr drug dose of 30 mg/kg. The fa/fa rats received both D-CAR and L-CAR starting from the sixth week of age and the treatment continued until the 30th week of age. The dose of both the CAR enantiomers was chosen to be lower than that of pyrydoxamine (more than 2.5-folds on molar level), used by
Plasma, urine and tissue sampling
Indirect systolic blood pressure (SBP) and heart rate measurements
At baseline and throughout the experiment, SBP was measured monthly in conscious rats by tail-cuff plethysmography [35] . [36] . Lipofuscins were spectrofluorimetrically determined according to the method reported by [37] , setting the excitation/emission wavelengths at 330 nm and 455 nm, respectively.
Plasma parameters
Plasma levels of cholesterol, triglycerides, glucose, creatinine and insulin were measured using available and specific enzymatic-colorimetric kits, and in accordance with the manufacturer's instructions. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated from fasting glucose and insulin levels as a measure of insulin resistance
Urinary parameters
Renal disease was assessed by measuring the 24 hr urinary excretion of albumin, total urinary protein and creatinine, using commercially available kits. The glomerular filtration rate (GFR; ml/min.) was calculated based on 24-hr urine creatinine clearance, using the standard formula C ϭ U*V/P*1440, where U is the creatinine concentration in urine (mg/ml), V is the 24-hr urine volume, and P is the plasma creatinine concentration (mg/ml). The levels of 8-epi-prostaglandin F2␣ (8- 
Protein carbonylation
Protein carbonyl content (PCOs) was quantified by reaction with 2,4-dinitrophenylhydrazine (2, according to [41] with slight modifications (increased washings to quantitatively remove un-reacted DNPH). Total PCOs were determined from the absorbance at 366 nm using a molar absorption coefficient of 22,000/M/cm [41] , and expressed as nmoles/mg protein.
Cholesterol and triglycerides content
Total cholesterol and triglycerides content (g/mg protein) in S 9.000 kidney fraction (0.25 g/ml) were determined by using commercial kits (Sentinel Diagnostic) and following the procedure described by Allain CC et al. [42] . [15] . Briefly [43] , with determination of hydroxyproline content by the method of Reddy and Enwemeka [44] following acid hydrolysis [45] . Collagen amount in tail tendon samples was calculated assuming 14% content of hydroxyproline [46, 47] 
Plasma, urine and tissue levels of carnosine
Plasma and urine levels of L-and D-CAR were determined by the HPLC-MS/MS method previously developed and validated
Results
In silico studies Figure 1 Figure 3 [9, 49] , the age-dependent increase of body weight in ZK was associated to a significant increase in plasma cholesterol and triglycerides, but not in plasma glucose, over the 24 week period (Fig. 4) Figure 4 . As compared to ZK rats, plasma cholesterol (Fig. 4B) and triglycerides (Fig. 4C) 
In vivo studies Pharmacokinetic profile of L-CAR and D-CAR in the rat
Effect of L-and D-CAR supplementation on metabolic syndrome risk factors Water and food intake All the 12 LN (Fa/Fa) and 36 ZK (fa/fa) rats participating in the study survived up to the end of the experiment and appeared generally healthy. The water intake was not significantly different among the four groups (data not shown), although food intake significantly increased from 24 Ϯ 5 g/day in LN rats to 35 Ϯ
g/day in ZK rats (P Ͻ 0.05). Food intake was also increased in ZK ϩ D (33 Ϯ 4 g/day) and ZK ϩ L rats (30 Ϯ 6 g/day) (P Ͻ 0.01 versus LN; not significant versus ZK) (data not shown).
Anti-obesity effect At the beginning of the study, the 6-week-old LN animals weighed significantly less than ZK rats (Table 1). All animals gained weight throughout the study period, and at the end of the experiment (30 weeks) the body weight of ZK rats was significantly higher (ϩ53.5%) than that of LN animals (Fig. 4A). In both the groups supplemented with L-CAR and D-CAR the body weight gain was significantly restrained compared to ZK (ϩ35.8% and ϩ40% respectively versus LN; -12% and -9% versus ZK), indicating a significant anti-obesity effect of both the enantiomers.
Hypolipidaemic effect Plasma -Table 1 summarizes the plasma parameters relative to LN and ZK rats at the beginning of the study. Among all the considered parameters, only the body weight was found significantly different between the two groups. In line with previous results
. In particular, in ZK rats, the plasma cholesterol and triglycerides levels were elevated by 2.4-and 7.0-fold, respectively, compared to LN animals. The changes in metabolic parameters that occurred in L-and D-carnosine-fed rats after 24 weeks are shown in
levels were significantly reduced in both ZK ϩ L and ZK ϩ D animals. Although D-CAR was slightly more effective than L-CAR in decreasing cholesterol (-45% versus -40%) and triglycerides (-43% versus -35%), overall, no statistically significant differences were observed between the two treated ZK groups.
Fig. 2 In vitro studies: kinetics of the enzymatic hydrolysis of L-CAR (triangle) and D-CAR (square) in (A) human serum, (B) rat kidney and (C) human liver.
Fig. 3 Time course of L-CAR (triangle) and D-CAR (square) in rat plasma, after oral administration of 100 mg/kg.
Kidney -The total cholesterol content (g/mg protein) in kidney was 2.4-fold increased in ZK (
Insulin/glucose levels
In agreement with previous studies [9, 49] (Fig. 4D) . At the beginning of the study (6 (Fig. 4E) , as reported by other authors [13, 50] . L-and D-CAR treatment significantly restrained the development of hyperinsulinaemia (28.08% and 33.03% reduction, respectively) (Fig. 4E) .
mmol/l). Treatment with L-or D-CAR did not significantly affect the plasma glucose levels
As expected, the ZK rats had greater insulin resistance, expressed as HOMA-IR, than did the LN rats and this parameter was significantly improved in both the ZK ϩ L and ZK ϩ D animals (Fig. 4F) .
Anti-hypertensive effect
At the baseline, mean SBP was almost superimposable in all the experimental groups, ranging from 118 Ϯ 4 to 126 Ϯ 4 mmHg (Fig. 5) . In accordance with the literature data [39] , the monthly evaluation showed a time-dependent increase of SBP in ZK but not in LN rats (Fig. 5) . At the end of the study (30 (Fig. 6A) . A more pronounced protective effect was induced by both the compounds on [51] (Fig. 6C) . (Fig. 6B) 
weeks), the untreated ZK rats developed a significant hypertensive status, as demonstrated by the significant rise in SPB (ϩ42%) compared to LN animals. The magnitude of SBP elevation was significantly restrained in ZK rats treated with either L-and D-CAR, and the extent of decrease was quite similar and not significantly different at all the time-points. In particular, the SBP values measured at the end of the experiment in ZK ϩ L and ZK ϩ D treated animals (Fig. 5) were reduced by 11.5% (145 Ϯ 3 mmHg) and 15.7% (137 Ϯ 4 mmHg), respectively. No changes in heart rate measurements were observed in the four experimental groups, neither at the start nor at the end of the study (data not shown).
Renal function The onset and progression of the renal damage in obese rats, as well as the protective effect of L-and D-CAR, were evaluated by considering several indicators such as plasma and urine creatinine levels (24 hrs), urinary excretion of total proteins and albumin (24 hrs), as well as by light and electron microscopy analysis of the kidney tissue. A 2.4-fold increase in plasma creatinine concentration was observed in ZK compared to LN rats (P Ͻ 0.001), an effect that was significantly restrained by both L-CAR (-31.7% versus ZK; P Ͻ 0.001) and D-CAR (-36% versus ZK; P Ͻ 0.001) (data not shown). A similar protective trend was also observed by considering the urinary albumin, creatinine and protein excretions, which were increased 14-fold (P Ͻ 0.001), 2.5-fold (P Ͻ 0.001) and 6.8-fold (P Ͻ 0.001), respectively, in ZK rats compared to the LN animals. Both L-CAR and D-CAR provided a significant protection against the development of proteinuria/albuminuria/creatininuria, which was restrained by approximately 50% (data not shown). The overall renoprotective effect of both the compounds is well described by the parameters reported in Figure 6. Creatinine clearance (expressed as GFR), was reduced by 45.8% in ZK compared to LN rats, and was significantly improved by both L-CAR (ϩ28.3% versus ZK) and D-CAR (ϩ25.1% versus ZK)
The 35-fold increase observed in ZK compared to LN animals was, in fact, restrained by 65-70% in both L-and D-CAR treated animals. As previously reported for plasma parameters D-CAR was slightly, but not significantly, more effective than L-CAR in reducing all the indicators of renal impairment. Light microscopy examinations clearly indicate the development of glomerulosclerosis (mild degree) and tubulointerstitial damage in 30 week ZK rats when compared with those of age-matched control LN, in accordance with the literature data [52] (data not shown). These glomerular and interstitial changes, although appearing less common in ZK ϩ L and ZK ϩ D versus ZK rats, were not significantly modified by both treatments (data not shown), which conversely were able to slightly but significantly restrain the increase in the mean glomerular diameter
Oxidative/carbonyl stress indices
The urinary excretion rate of cyclooxygenase metabolites, determined at the end of experiments, is reported in Table 2) .
Studies on urine fluorescence have been previously reported to correlate with the concentrations of AGEs, and increased levels of AGEs have been associated with aging and with the onset and development of chronic and degenerative diseases, renal injury included [38, 53]. The results of this study show that the 24 hr urinary excretion of AGEs (FU/mg creatinine/24 hr), as determined by the measurement of their typical fluorescence, was 3.3-fold increased in ZK compared to LN rats, despite the reduced GFR, and were significantly reduced in both the treated groups, by 45-47% (
By applying a recently developed LC-MS/MS method [14], we have shown that the Michael adduct between CAR and HNE is a stable and reliable biomarker of lipid peroxidation and carbonylation in vivo. By demonstrating higher levels of this adduct in urine from ZK rats compared to LN animals, we confirmed HNE overproduction in obese animals and the role of CAR as an endogenous detoxifying agent of RCS. The same analytical approach was applied in this study to confirm the in vivo RCS-trapping ability of exogenous L-and D-CAR. Figure 8 summarizes these results and shows typical LC-ESI-MS/MS profiles of urine, relative to the four groups of animals, acquired in MRM by setting the precursor ion at m/z 383.1 (CID@40.00 V). As reported in Table 2, the CAR-HNE levels increased 6.3-fold in ZK rats compared with LN animals. The treatment with L-CAR provides a further 1.7-fold increase in CAR-HNE levels compared to ZK rats, and D-CAR was slightly, but not significantly, more effective (2.2-fold increase).
Solubility of collagen isolated from tail tendon of control and obese rats was taken as an indicator of the extent of collagen crosslinking. As shown in Table 2 , tail collagen from ZK rats was significantly more crosslinked than that of control animals, based on its decreased solubility in acetic acid (56.1% reduction [55, 56] . RCS are well known to induce chemical modification and crosslinking of renal and vascular collagen, thus to induce thickening and loss of elasticity of vascular wall, contributing to hypertension development [57, 58] [60] . The inhibitory effect of HNE on endothelial nitric oxide production is also mediated by a significant dimethylarginine dimethylaminohydrolase enzyme activity, leading to an increased bioavailability of nitric oxide synthase inhibitors [61, 63] [68] . However, it has been recently reported that carnosine has a relatively lower binding constant with Cu(II) ions as compared to histidine, which seems to exclude a metal ion chelating mechanism [69] . Also, a mechanism based on a direct radical scavenging should be excluded. The real antioxidant/radical scavenging activity of CAR is controversial and in particular it has been suggested that CAR cannot be as effective in vivo as other antioxidants such as ␣-tocopherol [68] . To further exclude a radical scavenging/ antioxidant mechanism of CAR, it has been recently observed that a fortified antioxidant diet designed to incorporate direct radical scavenging antioxidants (vitamin E, ascorbic acid, ␤-carotene) and substances acting to fortify oxidative stress-reducing enzymes (selenium, zinc, copper, manganese) were ineffective in reducing arterial pressure, cholesterol, insulin resistance and nephropathy in male obese Zucker rats [70] . The in vivo antioxidant activity of CAR could be addressed to the RCS quenching activity and to the inhibition of AGE formation, a wellknown pro-oxidant species. In fact, it is well known that RCS such as HNE act as a pro-oxidant by inducing the formation of ROS [71] , peroxides and by depleting endogenous antioxidants such as GSH [72] .
Carnosine levels in plasma, urine and renal tissue
Plasma, urine and tissue concentration of L-and D-CAR were determined at the end of the experiment in the four experimental groups (Table 3). Plasma concentration of endogenous CAR was reduced, but not significantly, in ZK compared to LN animals and was not statistically different following the chronic treatment with L-CAR. By contrast, more than a 10-fold increase was observed in ZK ϩ D treated animals. As expected, the urinary concentration of D-CAR was found to be greatly increased in ZK ϩ D rats, in respect to LN and ZK ϩ L rats. The kidney content of carnosine in ZK rats was slightly, but not significantly, reduced in respect to LN rats. Treatment with L-CAR provided a slight increase in CAR content compared to ZK rats (1.6-fold increase), and D-CAR was markedly more effective, providing a 14.4-fold increase in tissue levels. The higher amount of D-CAR in respect to L-CAR in urine and plasma are explained by considering that during the 24 hrs in
Hence 
